Toxicity is crucial in biological research and plays an important role in drug development. Toxicity studies aim to remove toxic compounds early in the drug development process, as drug-induced toxicities are the leading cause of drug failures.

Organ-specific toxicity tests—specifically the kidney—are of high interest as a central detoxification organ for their high exposure to drugs, reactive metabolites, and environmental chemicals. Kidney toxicity is routinely assessed during preclinical safety evaluations.

Invitrogen ProcartaPlex immunoassays for kidney toxicity enable the simultaneous quantification of up to 11 targets in a single well. These assays are available as single targets, preconfigured panels of targets, and custom-blended Mix & Match panels.

• Measure multiple biomarkers—analyze up to 11 toxicity targets (including FDA-recommended biomarkers*) at the same time
• Use several sample types—optimized for urine, serum/plasma, or cell culture supernatant samples
• Profile more biomarkers with less sample—multiple biomarkers in the same well means less sample input